Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study
| العنوان: | Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study |
|---|---|
| المؤلفون: | Amy E. DeZern, Bhagirathbhai Dholaria, Richard J. Jones, Vikas Gupta, Siddharth Kunte, Asad Bashey, Aaron T. Gerds, Anurag K. Singh, Michael R. Grunwald, Roni Tamari, Michael Ozga, Hany Elmariah, Auro Viswabandya, Lisa Rybicki, Alla Keyzner, Madiha Iqbal, Sameem Abedin, Tania Jain |
| المصدر: | Leukemia |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, Male, Cancer Research, medicine.medical_specialty, Transplantation Conditioning, Cyclophosphamide, Neutrophils, medicine.medical_treatment, Splenectomy, Graft vs Host Disease, Gastroenterology, Article, Internal medicine, Humans, Transplantation, Homologous, Medicine, Cumulative incidence, Myelofibrosis, Aged, Bone Marrow Transplantation, Retrospective Studies, Neutrophil Engraftment, business.industry, Incidence (epidemiology), Retrospective cohort study, Hematology, Middle Aged, Myeloablative Agonists, medicine.disease, Treatment Outcome, surgical procedures, operative, medicine.anatomical_structure, Oncology, Primary Myelofibrosis, Female, Bone marrow, Neoplasm Recurrence, Local, business, medicine.drug |
| الوصف: | We report the results from a multicenter retrospective study of 69 adult patients who underwent haploidentical blood or marrow transplantation (haplo-BMT) with post-transplantation cyclophosphamide (PTCy) for chronic phase myelofibrosis. The median age at BMT was 63 years (range, 41-74). Conditioning regimens were reduced intensity in 54% and nonmyeloablative in 39%. Peripheral blood grafts were used in 86%. The median follow-up was 23.1 months (range, 1.6-75.7). At 3 years, the overall survival, relapse-free survival (RFS), and graft-versus-host-disease (GVHD)-free-RFS were 72% (95% CI 59-81), 44% (95% CI 29-59), and 30% (95% CI 17-43). Cumulative incidences of non-relapse mortality and relapse were 23% (95% CI 14-34) and 31% (95% CI 17-47) at 3 years. Spleen size ≥22 cm or prior splenectomy (HR 6.37, 95% CI 2.02-20.1, P = 0.002), and bone marrow grafts (HR 4.92, 95% CI 1.68-14.4, P = 0.004) were associated with increased incidence of relapse. Cumulative incidence of acute GVHD grade 3-4 was 10% at 3 months and extensive chronic GVHD was 8%. Neutrophil engraftment was reported in 94% patients, at a median of 20 days (range, 14-70). In conclusion, haplo-BMT with PTCy is feasible in patients with myelofibrosis. Splenomegaly ≥22 cm and bone marrow grafts were associated with a higher incidence of relapse in this study. |
| تدمد: | 1476-5551 0887-6924 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51441f7a52b7eeb8bb029a59b3c5f7a0Test https://doi.org/10.1038/s41375-021-01449-1Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....51441f7a52b7eeb8bb029a59b3c5f7a0 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14765551 08876924 |
|---|